



EVENT BOOK

11th June 2021

SANOFI 



SUMMARY

Welcome Letter 5

Logistics Information 6

Program..... 8

SPEAKERS BIOGRAPHIES

Prof Harry Sokol, MD, PhD..... 9

Prof Nikolaos Papadopoulos, MD, PhD 10



Welcome Letter

Dear Participant,

It's a real honour to welcome you to our 5th Global Microbiota Summit.

For this 5th event, we have changed the format of the Summit, in order to provide a **more personalised experience**. The **topics on our agenda have been selected by you and your peers**, it is possible **to register only for the specific event(s) that best suit(s) your needs** while still being able **to access to networking sessions** with colleagues from around the world.

This year we will be holding three webinars aiming **to raise awareness of the role of the microbiota in Allergy, Immunity, Irritable bowel syndrome (IBS), Digestion and Nutrition**. However, our enduring goal remains the same; to provide an environment where the principal players in the field can directly share their insights and priorities in microbiota research.

In the extraordinary environment of a world-wide pandemic that has so dramatically altered the way we live and work, we have decided **once again to hold the summit as a virtual event**. We are happy to provide a platform that will give attendees the opportunity **to engage, network and collaborate with world renowned scientific experts**. Our aim is to foster the exchange of creative ideas while creating long-lasting relationships to build a thriving, international community.

Finally, we would like to express our deep appreciation for the many individuals who made this Summit possible. We are particularly grateful to our speakers for sharing their passion, expertise and unique perspectives to create this unforgettable experience.

Yours sincerely,

A handwritten signature in black ink, appearing to read 'Etienne Pouteau', enclosed within a large, stylized circular scribble.

Dr. Etienne Pouteau, PhD
Global Medical Head for
Digestive Wellness


Logistics Information

JOINING A WEBINAR BY INVITATION LINK

1. Click the link in the invitation e-mail to open the webinar.
(First time users will be prompted to download and run Zoom. Follow system commands to do so.)
2. If system dialog appears, "Allow" system to open Zoom Meetings.
3. If prompted, finish registration by entering the requested information.
4. Click "Join Audio Conference by Computer"

BEFORE THE WEBINAR STARTS

If you access to the webinar before the establish hour, you will see this popup:



DURING THE WEBINAR, THE ZOOM WINDOW



FULL SCREEN

- Enter Full Screen mode by clicking the Full Screen icon (usually on the upper right), or double-click anywhere on the Zoom window.
- Exit Full Screen mode by pressing ESC on your keyboard, or double-click anywhere on the Zoom window.

MINIMIZE

- If you minimize the Zoom window, you will see a thumbnail on your desktop. Click the Exit Minimized Video icon to return to the larger webinar view.




INTERPRETATION

- This is the icon for interpretation, open it to listen to simultaneous translation in your own language.


INTERACTIONS

- Use the buttons on your Toolbar to ask a Question.



QUESTION & ANSWER

1. Click Q&A to open the Q&A window. You can move this window around your screen.
2. Type your question into the Q&A box.
3. Click Send.
4. If the question is for webinar facilitators, Sanofi will reply via text. You will see a reply in the Q&A window.
5. If the question is for the speaker, the moderator will do a preselection and the speaker will answer your question live (out loud) during the interactive Q&A session.



POLLING

- During the webinar, speakers will run a poll with you. When this happens a pop-up box similar to the following will appear on your screen. You can then select your choice and then hit submit.

Webinar 1: Allergy & Immunity

TIME CET (UTC+2)	TOPICS	SPEAKER
09:00–09:05 20:00–20:05*	Welcome and introduction	Sanofi
09:05–09:45 20:05–20:45*	Susceptibility to Lung Viral Infection: a role for the Gut Microbiome? voted by 890 HCPs 	Prof Harry Sokol, MD, PhD
09:45–10:25 20:45–21:25*	The impact of Microbiome on the development of Allergic Diseases voted by 1873 HCPs 	Prof Nikolaos Papadopoulos, MD, PhD
10:25–10:55 21:25–21:55*	Interactive Q&A	All
10:55–11:00 21:55–22:00*	Conclusions and closing remarks	Sanofi

*alternative times for the same webinar



Prof Harry Sokol, MD, PhD

Prof Sokol, is from the Gastroenterology Department at the Saint Antoine Hospital (APHP, Paris, France), Co-director of the Microbiota, Gut & Inflammation team (INSERM CRSA UMRS 938, Sorbonne University, Paris) and Group leader at the Micalis Institute (INRA).

Prof Sokol is an internationally recognised expert in the fields of Inflammatory Bowel Disease (IBD) and the gut microbiota. He has published more than 190 papers on these topics in major journals (including Gut, Gastroenterology, Cell Metabolism, Cell Host & Microbe, Nature Communications, Nature Medicine). His work on the role of the gut microbiota in the pathogenesis of IBD led to landmark papers describing the IBD-associated dysbiosis (imbalance in gut microbiota composition) and the role of the pivotal commensal bacteria *Faecalibacterium prausnitzii* in gut homeostasis and in IBD.

Currently, his work focuses on deciphering the gut microbiota-host interactions in health and disease (particularly IBD), in order to better understand their role in pathogenesis and to develop innovative treatments. Prof Sokol is exploring particularly the role of the microbiota in tryptophan metabolism for which he is the recipient of an ERC grant.

Besides his interest in the fundamental science, he is also involved in translational research. He is the current president of the French group of Faecal Microbiota Transplantation ([HYPERLINK "http://www.gfff.fr" www.gfff.fr](http://www.gfff.fr)) and the head of the APHP Faecal Microbiota Transplantation Centre, he coordinated a pilot randomised control trial evaluating faecal microbiota transplantation in Crohn's disease and he is currently coordinating two phase III nationwide randomised control trials evaluating this approach in ulcerative colitis and Crohn's disease.

Susceptibility to Lung Viral Infection: a role for the Gut Microbiome?

What you will learn:

- The gut microbiome, composition, main functions and particularly its role in immunity.
- The potential role in COVID-19 and other viral pulmonary infections.
- The strong rationale for the use of microbiome-targeted interventions in viral lung infections.

Prof Nikolaos Papadopoulos, MD, PhD

Prof Papadopoulos is Professor of Allergy and Pediatric Allergy at the University of Athens (NKUA), Greece and at the University of Manchester, UK. He is also Professor of Allergy, Immunity & Infection at the Observational & Pragmatic Research Institute, Singapore.



Prof Papadopoulos has extensive clinical and educational experience, heading a unit that cares for more than 7000 children with allergic diseases yearly, implementing state-of-the-art interventions and training medical students, resident paediatricians, allergists and other healthcare professionals. His research focuses on the interface between the microbial world and allergic disease, with emphasis on asthma and food allergy.

He has extensive experience in international research projects, such as PreDicta, GA2LEN, EUROPREVALL, iFAAM and FAST, currently co-ordinating the EU “Future and Emerging Technologies” project CURE that explores the role of virome dysbiosis in asthma. Prof Papadopoulos has published over 400 papers (h-index: 86), has received several international awards and is invited to speak at international scientific meetings more than 30 times a year.

Moreover, he has/is serving in Boards of EAACI, GA2LEN, WAO, EFA and ARIA. He was the 2013-2015 President of EAACI and the 2017-2019 President of the Respiratory Effectiveness Group (HYPERLINK “<http://www.effectivenessevaluation.org/>” REG). He is the Editor-in-Chief of “Frontiers in Allergy”.

The impact of Microbiome on the development of Allergic Diseases

What you will learn:

- Allergic diseases from environmental changes are a major public health problem.
- There is evidence that they are driven by microbiome dysbiosis which may begin long before clinical symptoms.
- The microbiota and its metabolites are capable of modulating immune responses and therefore may offer a potential therapeutic target.



MAT-GLB-2100819

